Cyclopentenyl Cytosine Induces Senescence in Breast Cancer Cells Through the Nucleolar Stress Response and Activation of P53
Overview
Pharmacology
Affiliations
The induction of senescence has emerged as a potentially important contributor to the effects of chemotherapeutic agents against tumors. We have demonstrated that depletion of CTP induced by cyclopentenyl cytosine (CPEC; NSC 375575), a specific inhibitor of the enzyme CTP synthetase, induces irreversible growth arrest and senescence characterized by altered morphology and expression of senescence-associated β-galactosidase activity in MCF-7 breast cancer cells expressing wild-type p53. In contrast, differentiation in the absence of senescence resulted from CPEC treatment in MDA-MB-231 breast cancer cells that express a mutated p53. Both senescence of MCF-7 cells and differentiation of MDA-MB-231 cells were prevented by repletion of CTP through the cytidine salvage pathway. Senescence in MCF-7 cells was associated with a G(2)- and S-phase arrest, whereas differentiation in MDA-MB-231 cells was associated with arrest in G(1) phase at 5 days. Mechanistic studies revealed that CTP depletion induced a rapid translocation of nucleolar proteins, including nucleostemin and nucleolin into the nucleoplasm. This nucleolar stress response resulted in a sustained elevation of p53 and the p53 target genes, p21 and Mdm2, in cells with wild-type p53. Furthermore, short interfering RNA-induced knockdown of p53 in MCF-7 cells treated with CPEC prevented cellular senescence and increased apoptotic cell death. We conclude that CTP depletion and the resulting nucleolar stress response results in a senescence-like growth arrest through activation of p53, whereas cells with mutated p53 undergo differentiation or apoptotic cell death.
Quadra-Stable Dynamics of p53 and PTEN in the DNA Damage Response.
Gupta S, Panda P, Silveira D, Ahuja R, Hashimoto R Cells. 2023; 12(7).
PMID: 37048159 PMC: 10093226. DOI: 10.3390/cells12071085.
In silico recognition of a prognostic signature in basal-like breast cancer patients.
Conte F, Sibilio P, Grimaldi A, Salvatore M, Paci P, Incoronato M PLoS One. 2022; 17(2):e0264024.
PMID: 35167614 PMC: 8846521. DOI: 10.1371/journal.pone.0264024.
Fu X, Xu L, Qi L, Tian H, Yi D, Yu Y Oncol Rep. 2017; 38(2):859-865.
PMID: 28656213 PMC: 5561869. DOI: 10.3892/or.2017.5750.
Small molecule compounds that induce cellular senescence.
Petrova N, Velichko A, Razin S, Kantidze O Aging Cell. 2016; 15(6):999-1017.
PMID: 27628712 PMC: 6398529. DOI: 10.1111/acel.12518.
Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin.
Liang S, Peng X, Li X, Yang P, Xie L, Li Y Oncotarget. 2014; 6(2):1020-30.
PMID: 25544759 PMC: 4359214. DOI: 10.18632/oncotarget.2741.